Lifeboat Foundation

Medically, AI is helping us with everything from identifying abnormal heart rhythms before they happen to spotting skin cancer. But do we really need it to get involved with our genome? Protein-design company Profluent believes we do.

Founded in 2022 in Berkeley, California, Profluent has been exploring ways to use AI to study and generate new proteins that aren’t found in nature. This week, the team trumpeted a major success with the release of an AI-derived protein termed OpenCRISPR-1.

The protein is meant to work in the CRISPR gene-editing system, a process in which a protein cuts open a piece of DNA and repairs or replaces a gene. CRISPR has been actively in use for about 15 years, with its creators bagging the Nobel prize in chemistry in 2020. It has shown promise as a biomedical tool that can do everything from restoring vision to combating rare diseases; as an agricultural tool that can improve the vitamin D content of tomatoes, and slash the flowering time of trees from decades to months; and much more.

Using DNA and proteins, scientists have created new synthetic cells that act like living cells. Blurring the line between artificial and living materials, these cells can be reprogrammed to perform multiple functions, opening the door to new synthetic biology tech that goes beyond nature’s abilities.

Cells get their structure and stability from their cytoskeleton, a crosslinked framework of proteins that encases and protects other components. Depending on the type of cell, this cytoskeleton can be flexible to different degrees and respond in different ways to their environment, giving cells their specialized abilities.

For the new study, scientists from the University of North Carolina at Chapel Hill developed synthetic, self-assembling cytoskeletons, built out of DNA, peptides and other genetic material.

Scientists have successfully engineered functional artificial cells in the lab that behave like living cells.

Advances in the development of cytoskeletal-like materials with modular structures and mechanics are pivotal for the engineering of synthetic cells. Now actin-mimetic supramolecular peptide networks have been designed using programmable peptide–DNA crosslinkers, giving rise to tunable tactoid-shaped bundles and mechanical properties that control spatial localization, the diffusion of payloads and shape changes within artificial cells.

Unlike the rigid skeletons within our bodies, the skeletons within individual cells—cytoskeletons—are changeable, even fluid. And when these cytoskeletons reorganize themselves, they do more than support different cell shapes. They permit different functions.

Little wonder, then, that scientists who build artificial cells hope to create synthetic cytoskeletons that act like natural cytoskeletons. Synthetic cytoskeletons capable of supporting dynamic changes in cell shape and function could enable the development of novel drug delivery systems, diagnostic tools, and regenerative medicine applications.

Synthetic cytoskeletons have incorporated building blocks such as polymers, small molecules, carbon nanotubes, peptides, and DNA nanofilaments. Mostly DNA nanofilaments. Although they offer programmability, they can be hard to fine tune. To get around this difficulty, scientists based at UNC Chapel Hill led by Ronit Freeman, PhD, investigated the relatively unexplored possibilities offered by peptides. Specifically, the scientists engineered artificial cells using a programmable peptide–DNA nanotechnology approach.

Generative A.I. technologies can write poetry and computer programs or create images of teddy bears and videos of cartoon characters that look like something from a Hollywood movie.

Now, new A.I. technology is generating blueprints for microscopic biological mechanisms that can edit your DNA, pointing to a future when scientists can battle illness and diseases with even greater precision and speed than they can today.

CRISPR has transformed gene editing, but still presents challenges in hard-to-transfect cells, such as pluripotent stem cells and primary cells.¹ The key to obtaining successful transfection in these cells lies in innovative workflows. Here Georges Müller, CEO and cofounder of SEED Biosciences, shares his perspective on why focusing on editing a single cell, rather than bulk cells, is a pivotal strategy to optimise CRISPR delivery.

Delivery of ribonucleoprotein (RNP) into cells is an essential factor for successful CRISPR gene editing. However, this is difficult to guarantee using traditional CRISPR gene editing methods, especially in hard-to-transfect cells. The standard CRISPR technique involves gathering a group of cells and then electroporating them, using short high-voltage pulses to overcome the barrier of their cell membranes. This allows bulk transfection of ribonucleoprotein (RNP) into the cells and then hopefully, nuclear translocation.

In this special episode, we’re joined by Cytosurge CSO Tobias Beyer, Ph.D., and SEED Biosciences CEO and Co-Founder Georges Muller, Ph.D., for an overview of gene editing with Cytosurge’s FluidFM® in combination with DispenCell™ dispensing technologies.

Tobias and Georges explain the FluidFM® technique and how it differs from traditional CRISPR methods along with the advantages the technology has over other methods of gene editing.

Continue reading “The Ins and Outs of Single Cell Gene Editing (Sponsored by Molecular Devices)” »

Rice University engineers have developed the smallest implantable brain stimulator demonstrated in a human patient. Thanks to pioneering magnetoelectric power transfer technology, the pea-sized device developed in the Rice lab of Jacob Robinson in collaboration with Motif Neurotech and clinicians Dr. Sameer Sheth and Dr. Sunil Sheth can be powered wirelessly via an external transmitter and used to stimulate the brain through the dura ⎯ the protective membrane attached to the bottom of the skull.

The device, known as the Digitally programmable Over-brain Therapeutic (DOT), could revolutionize treatment for drug-resistant depression and other psychiatric or neurological disorders by providing a therapeutic alternative that offers greater patient autonomy and accessibility than current neurostimulation-based therapies and is less invasive than other brain-computer interfaces (BCIs).

Continue reading “Rice team demonstrates miniature brain stimulator in humans” »

A first-ever dataset bridging molecular information about the poplar tree microbiome to ecosystem-level processes has been released by a team of Department of Energy scientists led by Oak Ridge National Laboratory. The project aims to inform research regarding how natural systems function, their vulnerability to a changing climate, and ultimately how plants might be engineered for better performance as sources of bioenergy and natural carbon storage.

The data, described in Nature Publishing Group’s Scientific Data, provides in-depth information on 27 genetically distinct variants, or genotypes, of Populus trichocarpa, a poplar tree of interest as a bioenergy crop. The genotypes are among those that the ORNL-led Center for Bioenergy Innovation previously included in a genome-wide association study linking genetic variations to the trees’ physical traits. ORNL researchers collected leaf, soil and root samples from poplar fields in two regions of Oregon — one in a wetter area subject to flooding and the other drier and susceptible to drought.

Details in the newly integrated dataset range from the trees’ genetic makeup and gene expression to the chemistry of the soil environment, analysis of the microbes that live on and around the trees and compounds the plants and microbes produce.